59717-9 |
Nordiazepam |
MCnc |
Bld |
Pt |
Qn |
Confirm |
|
ACTIVE |
Nordiazepam [Mass/volume] in Blood by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
20 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59717-9 |
|
Confirm |
|
|
Both |
|
|
|
0 |
Nordiazepam Bld Cfm-mCnc |
|
|
|
N |
|
Blood; Calmday; Cfm; Chlordiazepoxide metabolite; CNFR; CNFRM; Conf; Confirmation; Confirmatory; Desmethyldiazepam; Diazepam metabolite; Dimethyldiazepam; DRUG/TOXICOLOGY; Drugs; GCMS; LC/MS/MS; Level; Madar; Mass concentration; n-dimethyldiazepam; Nordaz; Nordazepam; Nordiaze; Point in time; Praxadium; Prazepam metabolite; QNT; Quan; Quant; Quantitative; Random; Stilny; Tranxilium N; Vegesan; WB; Whole blood |
2.73 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
59718-7 |
Nordiazepam |
MCnc |
Body fld |
Pt |
Qn |
|
|
ACTIVE |
Nordiazepam [Mass/volume] in Body fluid |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
20 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59718-7 |
|
|
|
|
Both |
|
|
|
0 |
Nordiazepam Fld-mCnc |
|
|
|
N |
|
B/F; BF; bod; Bodies; Body fluid; Body fluid, unsp; Calmday; Chlordiazepoxide metabolite; Desmethyldiazepam; Diazepam metabolite; Dimethyldiazepam; DRUG/TOXICOLOGY; Drugs; Fl; Fld; FLU; Fluid; Level; Madar; Mass concentration; n-dimethyldiazepam; Nordaz; Nordazepam; Nordiaze; Point in time; Praxadium; Prazepam metabolite; QNT; Quan; Quant; Quantitative; Random; Stilny; Tranxilium N; Vegesan |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
59719-5 |
Nordiazepam |
MCnc |
Body fld |
Pt |
Qn |
Confirm |
|
ACTIVE |
Nordiazepam [Mass/volume] in Body fluid by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
20 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59719-5 |
|
Confirm |
|
|
Both |
|
|
|
0 |
Nordiazepam Fld Cfm-mCnc |
|
|
|
N |
|
B/F; BF; bod; Bodies; Body fluid; Body fluid, unsp; Calmday; Cfm; Chlordiazepoxide metabolite; CNFR; CNFRM; Conf; Confirmation; Confirmatory; Desmethyldiazepam; Diazepam metabolite; Dimethyldiazepam; DRUG/TOXICOLOGY; Drugs; Fl; Fld; FLU; Fluid; GCMS; LC/MS/MS; Level; Madar; Mass concentration; n-dimethyldiazepam; Nordaz; Nordazepam; Nordiaze; Point in time; Praxadium; Prazepam metabolite; QNT; Quan; Quant; Quantitative; Random; Stilny; Tranxilium N; Vegesan |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
5972-5 |
Plasminogen activator tissue type Ag^20M post venistasis |
MCnc |
PPP |
Pt |
Qn |
IA |
|
ACTIVE |
Plasminogen activator tissue type Ag [Mass/volume] in Platelet poor plasma by Immunoassay --20 minutes post venistasis |
|
MAJ |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
COAG |
|
5972-5 |
|
IA |
|
|
Both |
|
|
|
0 |
tPA Ag 20M PPP IA-mCnc |
|
|
|
Y |
|
After; Antigen; Antigens; Blood plasminogen activator; COAGULATION; EIA; ELFA; ELISA; Enzyme immunoassay; Hematology; Heme; IAA; Level; Mass concentration; MEIA; Plas; Platelet poor plasma; PLG; PLGN; Point in time; Profibrinolysin; PST; QNT; Quan; Quant; Quantitative; Random; SUDS; Tissue plasminogen activator; TPA; t-PA; Vascular plasminogen activator |
2.58 |
1.0d |
|
|
|
|
|
|
|
|
|
|
Renamed Method from "Imm" to "IA" for consistency across classes (approved by Laboratory LOINC Committee 2016 12). |
0 |
59720-3 |
Nordiazepam |
MCnt |
Meconium |
Pt |
Qn |
Confirm |
|
ACTIVE |
Nordiazepam [Mass/mass] in Meconium by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/g |
20 ng/g |
|
|
|
|
|
DRUG/TOX |
|
59720-3 |
|
Confirm |
|
|
Both |
|
|
|
0 |
Nordiazepam Mec Cfm-mCnt |
|
|
|
N |
|
Calmday; Cfm; Chlordiazepoxide metabolite; CNFR; CNFRM; Conf; Confirmation; Confirmatory; Desmethyldiazepam; Diazepam metabolite; Dimethyldiazepam; DRUG/TOXICOLOGY; Drugs; GCMS; LC/MS/MS; Madar; Mass content; Mec; n-dimethyldiazepam; Nordaz; Nordazepam; Nordiaze; Point in time; Praxadium; Prazepam metabolite; QNT; Quan; Quant; Quantitative; Random; Stilny; Tranxilium N; Vegesan |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/g |
|
|
|
0 |
59721-1 |
Nordiazepam |
MCnc |
Ser/Plas |
Pt |
Qn |
Confirm |
|
ACTIVE |
Nordiazepam [Mass/volume] in Serum or Plasma by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
20 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59721-1 |
|
Confirm |
|
|
Both |
|
|
|
0 |
Nordiazepam SerPl Cfm-mCnc |
|
|
|
N |
|
Calmday; Cfm; Chlordiazepoxide metabolite; CNFR; CNFRM; Conf; Confirmation; Confirmatory; Desmethyldiazepam; Diazepam metabolite; Dimethyldiazepam; DRUG/TOXICOLOGY; Drugs; GCMS; LC/MS/MS; Level; Madar; Mass concentration; n-dimethyldiazepam; Nordaz; Nordazepam; Nordiaze; Pl; Plasma; Plsm; Point in time; Praxadium; Prazepam metabolite; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Stilny; Tranxilium N; Vegesan |
2.73 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
59722-9 |
Nordiazepam |
MCnt |
Stool |
Pt |
Qn |
Confirm |
|
ACTIVE |
Nordiazepam [Mass/mass] in Stool by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/g |
20 ng/g |
|
|
|
|
|
DRUG/TOX |
|
59722-9 |
|
Confirm |
|
|
Both |
|
|
|
0 |
Nordiazepam Stl Cfm-mCnt |
|
|
|
N |
|
Bowel movement; Calmday; Cfm; Chlordiazepoxide metabolite; CNFR; CNFRM; Conf; Confirmation; Confirmatory; Desmethyldiazepam; Diazepam metabolite; Dimethyldiazepam; DRUG/TOXICOLOGY; Drugs; Faecal; Faeces; Fecal; Feces; GCMS; LC/MS/MS; Madar; Mass content; n-dimethyldiazepam; Nordaz; Nordazepam; Nordiaze; Point in time; Praxadium; Prazepam metabolite; QNT; Quan; Quant; Quantitative; Random; Stilny; Stl; Stool = Fecal; Tranxilium N; Vegesan |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/g |
|
|
|
0 |
59723-7 |
Nordiazepam |
MCnt |
Tiss |
Pt |
Qn |
|
|
ACTIVE |
Nordiazepam [Mass/mass] in Tissue |
|
MIN |
DefinitionDescription |
|
|
ng/g |
20 ng/g |
|
|
|
|
|
DRUG/TOX |
|
59723-7 |
|
|
|
|
Both |
|
|
|
0 |
Nordiazepam Tiss-mCnt |
|
|
|
N |
|
Calmday; Chlordiazepoxide metabolite; Desmethyldiazepam; Diazepam metabolite; Dimethyldiazepam; DRUG/TOXICOLOGY; Drugs; Madar; Mass content; n-dimethyldiazepam; Nordaz; Nordazepam; Nordiaze; Point in time; Praxadium; Prazepam metabolite; QNT; Quan; Quant; Quantitative; Random; Stilny; Tissue; Tissue, unspecified; Tranxilium N; Vegesan |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/g |
|
|
|
0 |
59724-5 |
Cathine |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Cathine [Mass/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
5 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59724-5 |
|
|
|
|
Both |
|
|
|
0 |
Cathine SerPl-mCnc |
|
|
|
N |
|
Addiction; d-Norpseudoephedrine; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; Illicit; Level; Mass concentration; Norpseudoephedrine; Pl; Plasma; Plsm; Point in time; PotentialForAbuse; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.73 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
59725-2 |
Oxazepam |
MCnc |
Bld |
Pt |
Qn |
|
|
ACTIVE |
Oxazepam [Mass/volume] in Blood |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
20 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59725-2 |
|
|
|
|
Both |
|
|
|
0 |
Oxazepam Bld-mCnc |
|
|
|
N |
|
Alepam; Blood; Chlordiazepoxide metabolite; Diazepam metabolite; DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Point in time; Prazepam metabolite; QNT; Quan; Quant; Quantitative; Random; Serax; Temazepam metabolite; WB; Whole blood |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
59726-0 |
Oxazepam |
MCnc |
Bld |
Pt |
Qn |
Confirm |
|
ACTIVE |
Oxazepam [Mass/volume] in Blood by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
20 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59726-0 |
|
Confirm |
|
|
Both |
|
|
|
0 |
Oxazepam Bld Cfm-mCnc |
|
|
|
N |
|
Alepam; Blood; Cfm; Chlordiazepoxide metabolite; CNFR; CNFRM; Conf; Confirmation; Confirmatory; Diazepam metabolite; DRUG/TOXICOLOGY; Drugs; GCMS; LC/MS/MS; Level; Mass concentration; Point in time; Prazepam metabolite; QNT; Quan; Quant; Quantitative; Random; Serax; Temazepam metabolite; WB; Whole blood |
2.73 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
59727-8 |
Oxazepam |
MCnc |
Body fld |
Pt |
Qn |
|
|
ACTIVE |
Oxazepam [Mass/volume] in Body fluid |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
20 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59727-8 |
|
|
|
|
Both |
|
|
|
0 |
Oxazepam Fld-mCnc |
|
|
|
N |
|
Alepam; B/F; BF; bod; Bodies; Body fluid; Body fluid, unsp; Chlordiazepoxide metabolite; Diazepam metabolite; DRUG/TOXICOLOGY; Drugs; Fl; Fld; FLU; Fluid; Level; Mass concentration; Point in time; Prazepam metabolite; QNT; Quan; Quant; Quantitative; Random; Serax; Temazepam metabolite |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
59728-6 |
Oxazepam |
MCnc |
Body fld |
Pt |
Qn |
Confirm |
|
ACTIVE |
Oxazepam [Mass/volume] in Body fluid by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
20 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59728-6 |
|
Confirm |
|
|
Both |
|
|
|
0 |
Oxazepam Fld Cfm-mCnc |
|
|
|
N |
|
Alepam; B/F; BF; bod; Bodies; Body fluid; Body fluid, unsp; Cfm; Chlordiazepoxide metabolite; CNFR; CNFRM; Conf; Confirmation; Confirmatory; Diazepam metabolite; DRUG/TOXICOLOGY; Drugs; Fl; Fld; FLU; Fluid; GCMS; LC/MS/MS; Level; Mass concentration; Point in time; Prazepam metabolite; QNT; Quan; Quant; Quantitative; Random; Serax; Temazepam metabolite |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
59729-4 |
Oxazepam |
MCnt |
Meconium |
Pt |
Qn |
Confirm |
|
ACTIVE |
Oxazepam [Mass/mass] in Meconium by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/g |
20 ng/g |
|
|
|
|
|
DRUG/TOX |
|
59729-4 |
|
Confirm |
|
|
Both |
|
|
|
0 |
Oxazepam Mec Cfm-mCnt |
|
|
|
N |
|
Alepam; Cfm; Chlordiazepoxide metabolite; CNFR; CNFRM; Conf; Confirmation; Confirmatory; Diazepam metabolite; DRUG/TOXICOLOGY; Drugs; GCMS; LC/MS/MS; Mass content; Mec; Point in time; Prazepam metabolite; QNT; Quan; Quant; Quantitative; Random; Serax; Temazepam metabolite |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/g |
|
|
|
0 |
5973-3 |
Plasminogen activator tissue type Ag^10M post venistasis |
MCnc |
PPP |
Pt |
Qn |
IA |
|
ACTIVE |
Plasminogen activator tissue type Ag [Mass/volume] in Platelet poor plasma by Immunoassay --10 minutes post venistasis |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
COAG |
|
5973-3 |
|
IA |
|
|
Both |
|
|
|
0 |
tPA Ag 10M PPP IA-mCnc |
|
|
|
Y |
|
After; Antigen; Antigens; Blood plasminogen activator; COAGULATION; EIA; ELFA; ELISA; Enzyme immunoassay; Hematology; Heme; IAA; Level; Mass concentration; MEIA; Plas; Platelet poor plasma; PLG; PLGN; Point in time; Profibrinolysin; PST; QNT; Quan; Quant; Quantitative; Random; SUDS; Tissue plasminogen activator; TPA; t-PA; Vascular plasminogen activator |
2.73 |
1.0d |
|
|
|
|
|
|
|
|
|
|
Renamed Method from "Imm" to "IA" for consistency across classes (approved by Laboratory LOINC Committee 2016 12). |
0 |
59730-2 |
Oxazepam |
MCnc |
Ser/Plas |
Pt |
Qn |
Confirm |
|
ACTIVE |
Oxazepam [Mass/volume] in Serum or Plasma by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
20 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59730-2 |
|
Confirm |
|
|
Both |
|
|
|
0 |
Oxazepam SerPl Cfm-mCnc |
|
|
|
N |
|
Alepam; Cfm; Chlordiazepoxide metabolite; CNFR; CNFRM; Conf; Confirmation; Confirmatory; Diazepam metabolite; DRUG/TOXICOLOGY; Drugs; GCMS; LC/MS/MS; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; Prazepam metabolite; QNT; Quan; Quant; Quantitative; Random; Serax; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Temazepam metabolite |
2.73 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
59731-0 |
Oxazepam |
MCnt |
Stool |
Pt |
Qn |
Confirm |
|
ACTIVE |
Oxazepam [Mass/mass] in Stool by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/g |
20 ng/g |
|
|
|
|
|
DRUG/TOX |
|
59731-0 |
|
Confirm |
|
|
Both |
|
|
|
0 |
Oxazepam Stl Cfm-mCnt |
|
|
|
N |
|
Alepam; Bowel movement; Cfm; Chlordiazepoxide metabolite; CNFR; CNFRM; Conf; Confirmation; Confirmatory; Diazepam metabolite; DRUG/TOXICOLOGY; Drugs; Faecal; Faeces; Fecal; Feces; GCMS; LC/MS/MS; Mass content; Point in time; Prazepam metabolite; QNT; Quan; Quant; Quantitative; Random; Serax; Stl; Stool = Fecal; Temazepam metabolite |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/g |
|
|
|
0 |
59732-8 |
Oxazepam |
MCnt |
Tiss |
Pt |
Qn |
|
|
ACTIVE |
Oxazepam [Mass/mass] in Tissue |
|
MIN |
DefinitionDescription |
|
|
ng/g |
20 ng/g |
|
|
|
|
|
DRUG/TOX |
|
59732-8 |
|
|
|
|
Both |
|
|
|
0 |
Oxazepam Tiss-mCnt |
|
|
|
N |
|
Alepam; Chlordiazepoxide metabolite; Diazepam metabolite; DRUG/TOXICOLOGY; Drugs; Mass content; Point in time; Prazepam metabolite; QNT; Quan; Quant; Quantitative; Random; Serax; Temazepam metabolite; Tissue; Tissue, unspecified |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/g |
|
|
|
0 |
59733-6 |
Potassium |
MCnt |
Tiss |
Pt |
Qn |
|
|
ACTIVE |
Potassium [Mass/mass] in Tissue |
|
MIN |
DefinitionDescription |
|
|
mEq/g |
1 mEq/g |
|
|
|
|
|
DRUG/TOX |
|
59733-6 |
|
|
|
|
Both |
|
|
|
0 |
Potassium Tiss-mCnt |
|
|
|
N |
|
DRUG/TOXICOLOGY; Drugs; k; K+; Mass content; Point in time; Potass; QNT; Quan; Quant; Quantitative; Random; Tissue; Tissue, unspecified |
2.7 |
2.32 |
|
|
|
|
|
|
|
meq/g |
|
|
|
0 |
59734-4 |
Propoxyphene |
PrThr |
Ser/Plas |
Pt |
Ord |
Screen |
|
ACTIVE |
Propoxyphene [Presence] in Serum or Plasma by Screen method |
|
MIN |
DefinitionDescription |
|
|
|
50 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59734-4 |
|
Screen |
|
|
Both |
|
|
|
0 |
Propoxyph SerPl Ql Scn |
|
|
|
N |
|
Addiction; Algaphan; Cosalgesic; Cotonal-65; Darvon; Depronal; Dextrogesic; Dextropropoxyphene; Distalgesic; Dolasan; Doloxene; D-propoxyphene; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; Illicit; Napsalgesic; Ordinal; Pl; Plasma; Plsm; Point in time; PotentialForAbuse; PR; QL; Qual; Qualitative; Random; Scn; Scr; Screen; Scrn; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.73 |
2.32 |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect new model for ordinal terms; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
59735-1 |
Salicylamide |
MCnc |
Bld |
Pt |
Qn |
|
|
ACTIVE |
Salicylamide [Mass/volume] in Blood |
|
MIN |
DefinitionDescription |
|
|
ug/mL |
2 mcg/mL |
|
|
|
|
|
DRUG/TOX |
|
59735-1 |
|
|
|
|
Both |
|
|
|
0 |
Salicylamide Bld-mCnc |
|
|
|
N |
|
Blood; DRUG/TOXICOLOGY; Drugs; Level; Lobac; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; Salicylamid; Sinedol; Triaprin-DC; Utrosal; WB; Whole blood |
2.7 |
2.32 |
|
|
|
|
|
|
|
ug/mL |
|
|
|
0 |
59736-9 |
Salicylamide |
MCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Salicylamide [Mass/volume] in Urine |
|
MIN |
DefinitionDescription |
|
|
ug/mL |
2 mcg/mL |
|
|
|
|
|
DRUG/TOX |
|
59736-9 |
|
|
|
|
Both |
|
|
|
0 |
Salicylamide Ur-mCnc |
|
|
|
N |
|
DRUG/TOXICOLOGY; Drugs; Level; Lobac; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; Salicylamid; Sinedol; Triaprin-DC; UA; UR; Urn; Utrosal |
2.7 |
2.32 |
|
|
|
|
|
|
|
ug/mL |
|
|
|
0 |
59737-7 |
Selenium |
MCnt |
Nail |
Pt |
Qn |
|
|
ACTIVE |
Selenium [Mass/mass] in Nail |
|
MIN |
DefinitionDescription |
|
|
ug/g |
10 mcg/g |
|
|
|
|
|
DRUG/TOX |
|
59737-7 |
|
|
|
|
Both |
|
|
|
0 |
Selenium Nail-mCnt |
|
|
|
N |
|
DRUG/TOXICOLOGY; Drugs; Mass content; Nails; Point in time; QNT; Quan; Quant; Quantitative; Random; SE; Ungal nail |
2.7 |
2.32 |
|
|
|
|
|
|
|
ug/g |
|
|
|
0 |
59738-5 |
Silver |
MCnc |
Body fld |
Pt |
Qn |
|
|
ACTIVE |
Silver [Mass/volume] in Body fluid |
|
MIN |
DefinitionDescription |
|
|
ug/L |
0.5 mcg/L |
|
|
|
|
|
DRUG/TOX |
|
59738-5 |
|
|
|
|
Both |
|
|
|
0 |
Silver Fld-mCnc |
|
|
|
N |
|
Ag; B/F; BF; bod; Bodies; Body fluid; Body fluid, unsp; DRUG/TOXICOLOGY; Drugs; Fl; Fld; FLU; Fluid; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; Silv |
2.7 |
2.32 |
|
|
|
|
|
|
|
ug/L |
|
|
|
0 |
59739-3 |
Silver |
MCnt |
Nail |
Pt |
Qn |
|
|
ACTIVE |
Silver [Mass/mass] in Nail |
|
MIN |
DefinitionDescription |
|
|
ug/g |
0.5 mcg/g |
|
|
|
|
|
DRUG/TOX |
|
59739-3 |
|
|
|
|
Both |
|
|
|
0 |
Silver Nail-mCnt |
|
|
|
N |
|
Ag; DRUG/TOXICOLOGY; Drugs; Mass content; Nails; Point in time; QNT; Quan; Quant; Quantitative; Random; Silv; Ungal nail |
2.7 |
2.32 |
|
|
|
|
|
|
|
ug/g |
|
|
|
0 |